Umbilical cord blood (UCB) is increasingly being used for human hematopoietic stem cell (HSC) transplantation in children but often requires pooling multiple cords to obtain sufficient numbers for transplantation in adults. To overcome this limitation, we have used an ex vivo two-week culture system to expand the number of hematopoietic CD34 1 cells in cord blood. To assess the in vivo function of these expanded CD34 1 cells, cultured human UCB containing 1 3 10 6 CD34 1 cells were transplanted into conditioned NOD-scid IL2rc null mice. The expanded CD34
Introduction
Allogeneic hematopoietic stem cell (HSC) transplantation following myeloablative therapy is curative for many malignant, genetic, and autoimmune disorders (1) . Sources of stem cells for clinical transplantation include bone marrow, cytokine-mobilized peripheral blood, and umbilical cord blood (UCB) (2) (3) (4) (5) . Human UCB is increasingly used as a clinical source of HSC due to the advantages including immediate availability, high proliferative capacity, and the low incidence of severe GVHD in recipients (4, (6) (7) (8) (9) (10) (11) (12) (13) . However, successful human HSC transplantation is dependent on the absolute number of CD34 þ cells transplanted (14) (15) (16) (17) (18) (19) . In the case of UCB, this often requires the pooling of multiple cords to obtain the optimal CD34 þ cell dose (17, 18, 20) . Concerns related to the use of pooled cords include the possibility of graft-versus-graft as well as the unpredictable reconstitution of individual cords (17, 19, 20) .
Many laboratories are culturing UCB to increase the CD34 þ cell yield from a single cord (21) (22) (23) (24) (25) . Long-term cultures have been successful in expanding CD34 þ cell numbers, but maintaining HSC activity has been difficult This work was supported by National Institutes of Health Grants HL77642, AI46629, an institutional Diabetes Endocrinology Research Center (DERC) grant DK32520, a Cancer Center Core grant CA34196, the Beta Cell Biology Consortium, and the Juvenile Diabetes Foundation, International. Joseph Laning and Morey Kraus are employees of Viacell, Inc. Kristin Biber is a former employee of Viacell, Inc. Dale Greiner is a consultant and has grant support from Viacell, Inc. Leonard Shultz is a consultant for Viacell, Inc. The contents of this publication are solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health. (26) (27) (28) (29) (30) . Investigators rely on immunodeficient mice, particularly NOD-scid mice, to define the in vivo function of the cultured HSC. However, transplantation of cultured human HSC into NOD-scid mice has yielded only low engraftment, limited multilineage hematopoietic development, and few if any HSC-derived T lymphocytes (31) (32) (33) .
Recently, new immunodeficient murine mouse models that lack a functional common IL-2-receptor gamma chain (IL2rc null ) have been found to be superior in their support of human HSC engraftment (34) . These animals lack mature lymphocytes and NK cells, express other impairments in innate immunity, and are long-lived, permitting long-term studies of engraftment with human HSCs (34) .
In the present study, we used the NOD-scid IL2rc null mouse model to investigate the in vivo potential of human UCB stem cells following expansion of CD34 þ cells in a two-week culture system. Cultured UCB engrafted and developed into myeloid, erythroid, and B-lymphoid lineages, and when the recipients were pre-treated with TNFa, functional T lymphoid cells were generated. Engrafted mice produced antibody in response to immunization with Tdependent and T-independent antigens, which was enhanced by administration of the human B Lymphocyte Stimulator (BLyS) cytokine (also termed BAFF or TNFSF13B).
Materials and Methods

Mice. NOD.CB17-Prkdc
scid (abbreviated as NODscid) and NOD.Cg-Prkdc scid IL2rg tmWjl /Sz (abbreviated as NOD-scid IL2rc null ) mice have been described (35, 36) . Male and female 6-to 12-week-old mice of each strain were used in these studies. They were specific pathogen free, housed in microisolator cages, and given autoclaved food and on alternate weeks given autoclaved acidified water or sulfamethoxazole-trimethoprim-medicated water (Goldline Laboratories, Ft. Lauderdale, FL). All animal use was in accordance with the guidelines of the Animal Care and Use Committees of the University of Massachusetts Medical School and The Jackson Laboratory.
Antibodies. Anti-human a/b TCR was obtained from Becton Dickinson (San Jose, CA). Anti-human BDCA2 was obtained from Miltenyi (Auburn, CA). All other antibodies and isotype controls were obtained from BD Pharmingen (San Diego, CA). Antibodies were conjugated with FITC, PE, PerCP, APC, Alexa 405, Pacific Blue, or Alexa700.
Cell Preparation. Single-cell suspensions of bone marrow, spleen, and thymus were prepared from engrafted mice. Whole blood was collected in PBS containing EDTA. RBC in marrow and spleen were removed by lysis with a hypotonic solution. GlyA-stained bone marrow cells were not subjected to red blood cell lysis. Cells counts were performed using a Coulter Counter (Beckman, Miami, FL). Flow Cytometry. Single cell suspensions or whole blood were preincubated with rat anti-mouse FcR11b (2.4G2) to block Fc binding and then incubated with appropriate dilutions of specific antibodies. In all wells, PerCP-conjugated anti-mouse CD45 and APC-conjugated anti-human CD45 were included. Labeled cells were fixed in 1% paraformaldehyde for analysis. Whole blood was stained according to manufacturer's instructions (BD Biosciences, San Jose, CA). At least 50,000 events were acquired on either BD Biosciences LSRII or FACSCalibur instruments (BD Biosciences). All cells that were murine CD45 À and human CD45 þ were analyzed for the presence of multilineage differentiation. Bone marrow cells that were negative for murine CD45 were also analyzed for the presence of human RBC and their progenitors. Data acquisition and analysis was performed with BD FACSDiva (BD Pharmingen) and FlowJo (Tree Star, Inc., Ashland, OR) software.
Ex Vivo Culture of CD34 1 Human UCB Stem Cells. Cultured UCB stem cells were prepared by Viacell, Inc. (Cambridge, MA). Briefly, red blood cells were removed using a double-density Percoll Gradient (1.05/ 1.077 g/ml). The recovered UCB cells were lineagedepleted using Stem Cell Technologies (Vancouver, British Columbia, Canada) SCT 9 antibody cocktail (CD2, CD3, CD14, CD16, CD19, CD24, CD56, CD66b, GlyA). The lineage-depleted cells were cultured for seven days in Stemspan (Stem Cell Technologies) supplemented with defined lipid cocktail (Gibco, Carlsbad, CA), 50 lg/mL gentamycin (Abbott Laboratories, Chicago, IL), 100 ng/mL SCF (Amgen, Thousand Oaks, CA), 100 ng/ml Flt3-L (Amgen), and 100 ng/ml Tpo (R&D Systems, Minneapolis, MN). At day seven of culture, non-adherent cells were recovered, lineage depletion was repeated, and cells were cultured for an additional seven days. After two weeks in culture, the percentage and number of cell subsets was determined by flow cytometry.
Engraftment of Mice with Cultured CD34 Human Ig ELISA. Levels of human IgG and IgM were measured in mouse sera using an ELISA assay. Briefly, ELISA plates were coated with the F(ab9) 2 fragment of antihuman IgG or IgM (Jackson ImmunoResearch, West Grove, PA) overnight and blocked with 0.5% horse serum and 0.02% azide in PBS. Triplicate serial dilutions of sera were added, followed by biotinylated mouse anti-human IgL kappa or lambda (Ebiosience, San Diego, CA). Streptavidin alkaline phosphatase (Southern Biotech) was added, and the reaction visualized by addition of 1 mg/ml p-nitrophenyl phosphate (Sigma-Aldrich) in 1 M diethanolamine, 0.5 mM MgCl 2 . Color development was terminated after 30 min with 3M NaOH, and plates were read at 405 nm using an Emax ELISA plate reader (Molecular Devices, Sunnyvale, CA). The levels of human IgG and IgM in the sera were calculated using a standard curve (Jackson ImmunoResearch). Limits of detection were 3 ng/ml for IgM and 2 ng/ml for IgG.
Streptococcus Pneumonia ELISA. Antibodies specific for Streptococcus pneumoniae capsular polysaccharide serotypes 4 or 14 were measured in mouse sera as described (38) . The levels of antibody in the sera were calculated using a standard (US reference human pneumococcal antiserum; FDA, Rockville, MD).
Tetanus ELISA. Quantification of anti-tetanus antibody used a commercial ELISA kit (SCIMEDX Corpo- þ cells in each sample was determined and used to calculate the counts/CD3 þ T cell. Data are presented as mean cpm/1 3 10 5 human CD3 þ cells 6 1 SEM. Histology. Tissues were fixed in 10% neutral buffered formalin, embedded in paraffin, and sectioned at 5 lm. Antigen retrieval prior to immunohistochemical staining was performed by incubating the sections in 0.1 mol/l citrate buffer (pH 6.0) in an 800-W microwave oven for 15 min. The slides were stained on a Dako (Carpinteria, CA) automated immunostainer using the EnVision (Dako) staining procedure. The sections were incubated with the EnVision plus Dual Link reagent (a polymer conjugated with goat anti-rabbit Ig or goat anti-mouse Ig and horseradish peroxidase) for 30 min. The sections were reacted with diaminobenzidine and hydrogen peroxide for visualization and counterstained with hematoxylin. Negative controls induced species matched non-binding antibodies. A qualified pathologist (BAW) who was unaware of the treatment of the tissue donor evaluated all tissues.
Statistics. Results are expressed as mean 6 one standard error. Values of specified groups were compared with the unpaired Student's t test (GraphPad Software, Version 4.0, San Diego, CA). Statistical significance was assumed for P values of ,0.05. 
Results
Ex Vivo Expansion of CD34
1 Human UCB. Phenotype of Cells Recovered from a Two-Week Culture of Human UCB. Human UCB, cord blood cells were cultured for two weeks in the presence of a cytokine cocktail, and the number and phenotype of the nonadherent cells was determined. The average expansion of human CD45 þ cells and CD34 þ cells was ;68-fold and ;37-fold, respectively ( Table 1) . The UCB population put into culture was devoid of mature lymphoid and myeloid populations and contained 32.3 6 3.9% CD34 þ cells (Table 2) . Although the percentage of CD34 þ cells in the population recovered from culture (20.1 6 1.9%) was slightly lower than in the input population, the overall expansion led to an increase in the total number of CD34 þ cells recovered. Phenotypically, many two-week cultured CD34 þ cells co-expressed CD33 and CD13, suggesting they were early stem/progenitor cells in the granulocyte and monocyte lineages ( 
comprised ;3% of the recovered cells ( Table 2) .
Engraftment of Cultured Human UCB in NOD-scid and NOD-scid IL2rc null mice. The NOD-scid mouse has been the ''gold standard'' for in vivo analyses of human HSC for over 10 years (36, 37, (39) (40) (41) (42) (43) . We and others have recently described new immunodeficient mouse models based on the targeted mutation in the IL-2 receptor common c chain (34) . Therefore, we first compared the ability of cultured UCB to engraft in NOD-scid and NOD-scid IL2rc null mice. These stocks of mice were injected with cultured human UCB cells containing 1 3 10 6 CD34 þ cells and engraftment in the bone marrow was quantified twelve weeks later.
Low levels of human CD45 þ cell engraftment were observed in the bone marrow of NOD-scid mice (0.2 6 0.1%, n ¼ 8). In contrast, robust levels of human CD45 þ cells were generated in NOD-scid IL2rc null mice (24.3 6 6.6%, n ¼ 5, P , 0.001). Based on these data, all subsequent experiments were performed using NOD-scid IL2rc null mice as recipients. Short-and Long-Term Stem Cell Repopulating Potential of Cultured Human UCB. Two major human stem/progenitor cell populations have been described using immunodeficient mice engrafted with human HSC: one is termed short-term repopulating cell (STRC), the other longterm repopulating cell (LTRC) (44, 45) .
Short-Term Repopulating Cell Engraftment. Cultured human UCB containing 1 3 10 6 CD34 þ cells were injected into conditioned NOD-scid IL2rc null mice, and human cell engraftment in the bone marrow of the recipients was determined 3 weeks later.
Human CD45 þ cells comprised ;2% of total bone marrow cells (Table 3 ). To determine their lineage, we analyzed the subsets of human CD45 þ cells present in the marrow, specifically analyzing for the presence of cell populations that are known to comprise the short-term repopulation cell population in scid mice (44, 45 þ B cells were generated, but no detectable CD3 þ T cells were observed (Table 3) . Representative histograms are shown in Figure 1 . These data demonstrate that cultured UCB display human STRC capacity when transplanted into NOD-scid IL2rc null mice. Long-Term Repopulating Cell Engraftment. We next analyzed the subsets of human cells known to comprise the long-term repopulation cell population in scid mice (36 þ T cells in NOD-scid IL2rc null mice suggests that 1) T-cell progenitors fail to survive in culture, 2) an inhibitory component(s) restricting T-cell development is present, or 3) a factor required for the generation of human CD3 þ T cells in the host is absent. One critical factor may be TNFa, as it has been reported that TNFa promotes the in vivo generation of T cells in NOD-scid mice engrafted with human HSC (46) .
Human CD45 þ Cell Engraftment in TNFa-Treated NOD-scid IL2rc null Mice Transplanted with Cultured Human UCB. We next determined whether TNFa would enhance the ability of cultured UCB to generate T cells. NOD-scid IL2rc null mice pretreated with TNFa generated levels of human CD45 þ cells in the blood (3.1 6 0.8%; 7.1 6 2.4 3 10 4 /ml, n ¼ 32) equivalent to mice not given TNFa (4.4 6 1.1%; 10.0 6 0.2 3 10 4 /ml, n ¼ 27, P ¼ N.S., Fig. 2 ).
Levels of human CD45
þ cells in the bone marrow (23.3 6 4.4%; 6.5 6 1.3 3 10 6 , n ¼ 26) of TNFa treated mice were also equivalent to that in non-TNFa-treated mice (25.6 6 4.7%; 4.8 6 1.0 3 10 6 , n ¼ 19, P ¼ N.S.). The percent of CD45 þ cells in the spleen of mice pretreated with TNFa (38.6 6 6.2%, n ¼ 11) was significantly greater than that in mice not treated with TNFa (16.2 6 4.2%, n ¼ 12, P , 0.01). There was also a difference in cell numbers in non-TNFa-treated mice (2.6 6 0.9 3 10 6 ) and TNFa-treated mice (7.3 6 1.8 3 10 6 , P , 0.025). Non-TNFa-treated mice displayed undetectable (,0.05%, n ¼ 22) levels of human CD45 þ cell engraftment in the thymus whereas TNFa treated mice had readily detectable human CD45 þ cells (47.9 6 10.7% and 8.6 6 2.3 3 10 7 , P , 0.001, Fig. 2 ). Thymocytopoiesis and Human CD3 1 T-Cell Development in NOD-scid IL2rc null Mice Treated with TNFa and Transplanted with Cultured Human UCB. Thymus. In contrast with non-TNFa-treated mice that generated no human thymic engraftment, mice treated with TNFa developed CD3 þ T cells in the thymus (Fig. 3) . The human CD3 thymocytes displayed a normal distribution were analyzed by immunohistochemistry. Thymic sections of TNFa-treated mice contained human CD45 þ cells (A), which were localized predominantly in the subcapsular region. Many of these CD45 þ cells were CD5 þ (B) and expressed either CD4 þ (C) and/or CD8 þ (D). In addition, CD1a þ thymocytes were detected residing in the cortex of the thymus (E). TdT þ (F) and CD99 þ (G) thymocytes were also present, as were numerous human CD45 þ cells that expressed the proliferation antigen Ki-67 (H).
of immature double-positive CD4 þ CD8 þ thymocytes and mature single-positive CD4 þ and CD8 þ T cells. Histological analysis of thymic sections of TNFa-treated mice supports the flow cytometry data (Fig. 4) . Spleen. In contrast to non-TNFa-treated mice in which only very low levels of splenic CD3 þ T cells were detected, CD3 þ T cells were readily detected in the spleen of mice treated with TNFa (Table 4 and 3) and CD8 þ (56.1 6 6.9) T cells (Fig. 5) . Treatment with TNFa did not alter the percent or number of CD20 þ B cells.
Splenic sections of TNFa-treated mice displayed human CD45
þ cells predominantly in the white pulp (Fig.   6 ). Human CD20 þ B cells as well as human CD5 þ T cells were also identified. Human B cell maturation was documented by the presence of human CD138 þ plasma cells, which contain kappa and lambda light chains (Fig. 6) . Function of Human T and B Cells in TNFaTreated NOD-scid IL2rc null Mice Engrafted with Cultured Human UCB. To determine whether engrafted B cells were functional, we first quantified the concentrations of human Igs in the serum of mice engrafted 12 weeks earlier with cultured UCB. Levels of human IgM ranged from ;50 lg/ml to .250 lg/ml and levels of human IgG ranged from ;25 lg/ml to .250 lg/ml. The level of both IgG and IgM was increased in mice immunized with Pneumovax and treated with BLyS (Fig. 7A) . Low but detectable levels of IgM and IgG antibody to serotype 4 and serotype 14 of Streptococcus pneumoniae were detected following immunization with Pneumovax, and administration of recombinant human BLyS in mice boosted with Pneumovax significantly increased the concentration of IgM antibody to both serotypes (Fig. 7B) . Splenocytes obtained from TNFa-treated mice were cultured in the presence of human anti-CD3, anti-CD28, and anti-CD49d mAb for 64 hours. When adjusted for the number of human CD3 þ cells in the cultures, the proliferation of human CD3 þ cells in the spleen of engrafted TNFa-treated NOD-scid IL2rc null mice was only slightly lower than that of freshly isolated human T cells (Fig. 8A) . Finally, to determine if the functional T and B cells could collaborate to generate a T-dependent antibody response, mice were immunized with tetanus and boosted in the presence of recombinant human BLyS. Anti-tetanus antibody was detected in the serum of 2/7 of the immunized mice and 2/3 of mice boosted in the presence of BLyS (Fig.  8B) . 
Discussion
We have investigated the functional potential of human cord blood CD34 þ cells expanded in culture for two weeks to generate in vivo a multi-lineage human hematopoietic system and a functional human immune system. Cultured human UCB generated myeloid, erythroid, and lymphoidlineage cells in NOD-scid IL2rc null mice. Administration of TNFa facilitated the generation of human T cells. The immune system of these engrafted mice was functional as assessed by the presence of human Ig, and the ability to generate antibodies in response to immunization with either T-independent or T-dependent antigens.
Multiple sources of human HSC are now used for clinical transplantation, including mobilized peripheral blood hematopoietic stem cells, bone marrow, and umbilical cord blood (47, 48) . However, cord blood is emerging as the HSC source of choice due to the low cellular immunity of the passenger leukocytes, and the ease of identifying HLAmatches due to the observation that cord blood can be transplanted with a greater HLA disparity than can HSC from mobilized stem cells or bone marrow (8, 11) . One remaining barrier is that clinical transplantation of human UCB cells into adults is limited by the low yield of CD34 þ cells from a single cord. Currently, adult transplantation of the required CD34 þ cell dose necessitates the pooling of multiple cords, increasing the risk of GVHD as well as the need for matching to multiple donors [for review, see (49, 50) ]. Many approaches for ex vivo expansion of cord blood cells have been reported (21) (22) (23) (24) (25) (51) (52) (53) (54) (55) . In the culture system used in our studies, a substantial proportion of the cells phenotypically appeared to retain multi-lineage potential. To assess their in vivo potential, we adoptively transferred the cells into conditioned NOD-scid IL2rc null mice. The use of this stock of mice was used based on 1) earlier observations showing that human HSC engraft better than in NOD-scid mice (36, 56) and 2) our initial experiment comparing directly the ability of cultured HSC to engraft in these two strains. Although NOD-scid IL2rc null mice is the strain we chose for these in vivo analyses of human HSC, other strains of immunodeficient mice based on mutations in the IL-2 receptor gamma chain have been reported (34) . We recently compared engraftment in BALB/ c-Rag1 null IL2rc null mice with that of NOD-scid IL2rc null mice, and have determined that NOD-scid IL2rc null mice are much better recipients of human HSC (TP, unpublished observations). Moreover, additional modification of NODscid IL2rc null mice is currently underway, including the introduction of transgenes expressing human HLA (57) .
Previous studies comparing the in vivo engraftment kinetics and developmental potential of cultured UCB cells in immunodeficient mice have reported that cultured cells exhibit delayed engraftment (32, 33) . In our study, cultured HSC exhibited STRC capacity as evidenced by their ability to generate human myeloid and lymphoid cells within 3 weeks after transplantation. The cultured cells also exhibited LTRC capacity and serial transfer and engraftment of the bone marrow into secondary NOD-scid IL2rc null recipients suggests the maintenance of true HSC in the cultured population.
Few human T cells are observed following the injection of cultured HSC into NOD-scid mice (23, 32, 33) . In those studies, the percentages of human T cells were low, and the possibility of contaminating human T cells in the injected cell population was not excluded. In one study, cells recovered from the mice required ex vivo expansion in the presence of PHA and IL-2 to detect T cells (23) . We also observed that few cultured HSC develop into T cells in immunodeficient mice.
We hypothesized that the cultured cells may fail to produce TNFa, which increases T-cell lineage commitment and differentiation of human stem cells in NOD-scid mice transplanted with HSC (46) . Administration of exogenous TNFa prior to transplantation of cultured HSC augmented human thymus cell engraftment. These thymocytes migrated to the peripheral tissues leading to the generation of mature CD4 and CD8 T cells. How TNFa augments T-cell development is not known, but it has been reported that TNF enhances human T-cell generation in a xenogeneic fetal thymus organ culture, suggesting a direct effect on the engrafted stem cells (58) . However, experiments where cultured CD34 þ cells were treated with TNFa prior to injection into NOD-scid IL2rc null mice, no increase in T-cell development was observed (LJG and KB, unpublished observations). Alternatively, our data are consistent with the interpretation that TNF could have an indirect effect on the host environment in which the stem cells mature, possibly by activation of innate immunity and the induction of cytokines (59) . Multiple cytokines have been shown to enhance human HSC engraftment and differentiation in immunodeficient mice [recently reviewed in (57) ].
The human immune system generated by cultured HSC in NOD-scid IL2rc null mice was functional. Human IgG and IgM were detected in the circulation, and the mice were able to generate both T-independent and T-dependent antibodies in response to immunization with Pneumovax and tetanus, respectively. We note, however, that we only assayed the antibodies generated to 2 of the 23 serotypes of Pneumovax. We chose these two serotypes to analyze because they are two serotypes shared by both the pneumovax23 adult vaccine and the protein conjugated childhood vaccine (38) . Also, they elicit different responses in young versus older individuals: the response to serotype 4 is down in aged individuals whereas the response to serotype 14 remains high (60) . The ability to generate antibodies following immunization confirms the phenotypic and histological data showing that T cells, B cells, myeloid, and dendritic cells of human origin were generated. Equally important is that the allogeneic immune system that developed from the HSC in the expanded cord blood is tolerant to host, and could lead to the induction of donor-specific tolerance (61, 62) or for the treatment of autoimmune disorders (63) (64) (65) (66) .
In summary, human CD34 þ UCB cells expanded for two weeks in culture engraft and differentiate into multiple hematopoietic lineages in NOD-scid IL2rc null mice and generate a functional human immune system. Ex vivo expansion of UCB CD34 þ stem cells may be a promising alternative to pooling multiple cords for adult hematopoietic stem cell transplantation.
